Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair)
This is a discussion on Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) within the FDA News forum, part of the Industry News and Updates category; FDA is evaluating interim safety findings from an ongoing study of Xolair (omalizumab) that suggests an increased number of cardiovascular ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-16-2009, 02:39 PM
|
|||
|
|||
Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair)
FDA is evaluating interim safety findings from an ongoing study of Xolair (omalizumab) that suggests an increased number of cardiovascular and cerebrovascular adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group).
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) | industry_news | FDA News | 0 | 01-26-2009 12:09 PM |
| Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed a | industry_news | FDA News | 0 | 01-08-2009 03:32 PM |
| FDA issues an updated Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler). | industry_news | FDA News | 0 | 10-07-2008 10:37 AM |
| FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re | industry_news | FDA News | 0 | 06-07-2008 06:30 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 02:30 PM |
© 2008 DrugManagementForum™ powered by |
 |